CNBC
Novo Nordisk shares slide after guidance disappoints investors
Tuesday, August 4, 2026
Novo Nordisk raised its full-year financial guidance, but the increase fell short of investor expectations. The company is competing with Eli Lilly in the GLP-1 receptor agonist market for diabetes and weight loss treatments. Novo Nordisk's stock declined following the announcement.
Original reporting: https://www.cnbc.com/2026/08/04/novo-nordisk-releases-earnings-and-guidance.html